Cara Therapeutics (NASDAQ:CARA) Now Covered by StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of Cara Therapeutics (NASDAQ:CARA) in a research report issued to clients and investors on Friday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Cara Therapeutics Price Performance

Cara Therapeutics stock opened at $0.29 on Friday. The company has a market capitalization of $15.81 million, a PE ratio of -0.16 and a beta of 0.68. The firm has a fifty day simple moving average of $0.29 and a two-hundred day simple moving average of $0.37. Cara Therapeutics has a twelve month low of $0.24 and a twelve month high of $1.31.

Institutional Trading of Cara Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Disciplined Growth Investors Inc. MN lifted its stake in Cara Therapeutics by 6.6% in the second quarter. Disciplined Growth Investors Inc. MN now owns 1,935,718 shares of the biopharmaceutical company’s stock worth $499,000 after purchasing an additional 120,660 shares during the last quarter. FMR LLC raised its stake in shares of Cara Therapeutics by 18.5% during the third quarter. FMR LLC now owns 210,312 shares of the biopharmaceutical company’s stock valued at $65,000 after acquiring an additional 32,789 shares during the last quarter. Finally, XTX Topco Ltd bought a new position in shares of Cara Therapeutics during the third quarter valued at about $29,000. 44.66% of the stock is owned by institutional investors.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.